Fresenius Kabi Patent-Cliff Exposure & CMS Drug Spending Portfolio
Fresenius Kabi (Lake Zurich, IL): 68 reconciled FDA prescription therapies, $1.29B 2024 CMS Part D & Medicaid spend, and 143 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | Lake Zurich, IL |
| Reconciled FDA Portfolio Therapies | 68 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 0.0% |
| Primary Portfolio LOE Date | 2026-01-01 |
| 2024 CMS Total Public Spend | $1.29B |
| 2024 Medicare Part D Spend | $506.0M |
| 2024 Medicaid Spend | $783.5M |
| California HCAI SB 17 Filings | 143 WAC filings (max 362.0% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Fresenius / Fresenius Kabi across sibling Meru public-data platforms.